Will Doctors Survive AI? • Cannes Lineup • Genetics Testing • Cleerly vs Heartflow
Issue 46: The front page of longevity medicine - curated by doctors, for doctors.
Hey Docs,
I attended the 121st Explorers Club Gala surrounded by pioneers who’ve explored space, plunged into the Mariana Trench, and redefined our understanding of nature and space. Members include legends like Neil Armstrong, Buzz Aldrin, Jane Goodall, James Cameron, and Jeff Bezos.
But what struck me most wasn't just the stories, it was the spirit. Because I believe we, as longevity physicians, are explorers too.
We are charting a new frontier.
We’re stepping into the unknown without roadmaps, textbooks, or guarantees.
It’s risky. It’s lonely. People say we’re ungrounded, idealistic, even crazy.
But like any great expedition, what matters most isn’t the destination, it’s the journey and the crew.
The courage to lead without certainty.
The humility to learn every step of the way.
The camaraderie of knowing we’re not doing it alone.
Also… I tasted iguana, green crab gazpacho, worms, and snakehead
fish for the first time. That sense of curiosity? It fuels everything I do and everything we do at Longevity Docs.
Longevity medicine is still in its early days.
We’re not just practicing medicine, we’re reimagining it.
From how we test, treat, and teach to how we live, age, and lead.
The world might not fully understand what we’re building yet but explorers never wait for permission.
We move forward because we must.
Because discovery is worth the risk.
Let’s keep exploring together.
Happy Sunday!!!!
In this week’s newsletter:
Cover Story: Will Doctors Survive AI?
Inside Longevity Docs: Cannes Lineup
Buzz in the Chat: Genetic Testing • Cleerly vs. HeartFlow
Evidence-based Longevity: 3D Quantitative Transmission • AI Hospital
Business of Longevity: Inside Tracker AI • AI Hospital • Urine Cancer Screening
The Community Wire: Dr. Giovanni Campanile
The Calendar: Cannes Summit • Berlin • Portugal
Will Doctors survive AI? Discover the 5 Levels of Doctors in the Age of AI
We’re standing at the edge of a seismic shift. AI is no longer the future it’s the present. From diagnostic agents and virtual health coaches to personalized prescriptions and autonomous triage, artificial intelligence is infiltrating every layer of healthcare.
But here’s the real question: Where does that leave doctors?
This week’s cover story dives into the rise of "Super Docs": physicians who are not just surviving the AI wave, but mastering it. We break down the 5 Levels of Doctors in the Age of AI, and why those at the top will redefine the future of longevity medicine.
Twenty years ago, we had no smartphones, no social media, and no AI in our lives. Today, we can't imagine life without them. Healthcare is next in line for a massive transformation.
We're living through a paradigm shift in medicine. It reminds me what happened in parts of Africa, where countries leapfrogged from no telephone infrastructure straight into mobile banking. In the same way, we may bypass outdated, reactive healthcare and land directly into AI-enabled precision longevity medicine.
Consumers and startups are driving this change. They want care that is faster, cheaper, personalized, and always available and AI is making that possible.
We're entering an era where AI is embedded across the healthcare continuum from early detection and personalization to continuous health optimization and even AI companions for mental health.
It made me reflect: how can we map this onto a Maslow-like hierarchy of needs in longevity medicine?
🔺 The 5 Levels of Doctors in the Age of AI
Where do you stand in the new medical hierarchy?
Level 1: The Super Docs
Human + AI + Longevity vision
The rarest and most advanced physicians. They use AI agents to deliver personalized longevity protocols, optimize high performers, and operate like a hybrid between strategist, scientist, and coach. This is the future of elite, precision medicine and only a few will lead it.
Level 2: AI-Enhanced Docs
Human + AI for disease management
Doctors using AI to manage chronic conditions faster, better, and more efficiently but still focused on treating illness, not optimizing health.
Level 3: Autonomous AI agents
AI without humans
Fully AI-driven platforms managing triage, diagnostics, and even prescriptions for common conditions. Convenient, scalable, but not visionary.
Level 4: Preventive Doctors without AI
Human-only preventive care, low tech
Well-meaning, but limited. Practicing lifestyle medicine without leveraging data, automation, or precision tools. Soon to be outdated.
Level 5: Traditional Doctors
Human only, reactive, no tech
The status quo. Disease-focused, time-limited, and disconnected from the tech and data revolution. Still needed but not for the future of healthspan.
This isn’t just about tools, it’s about mindset.
Doctors who embrace AI won’t be replaced they’ll be augmented. They’ll become the architects of longer, healthier, more optimized lives. They’ll be the doctors patients seek out, investors bet on, and innovators want by their side.
So the real question is:
Which level of the Longevity Doctor Pyramid are you?
And more importantly, what are you doing to move up?
That’s exactly why we’re building the Certified Longevity Physician™ program:
to prepare doctors to lead the future of medicine with the science, tools, and vision that longevity care demands.
Announcing the First Speakers: Longevity Docs Summit – Cannes, June 25–26
From pioneer longevity physicians, billion-dollar companies founders, Fortune 500 executive to ministry of health, this is the room where the future of healthspan is negotiated.
This isn’t just a medical conference it’s where science, capital, and influence converge to shape the next 100 years of human potential.
Science & Medicine
From cellular medicine to gene therapy, peptides to plasma exchange, these are the pioneers turning longevity into clinical reality.
Dr. Eric Verdin – The latest science of aging
Dr. Elizabeth Yurth – Cellular medicine for longevity
Dr. Craig Koniver – The peptide revolution
Dr. Patrick Sewell – Gene therapy innovation
Dr. Dobri Kiprov – Therapeutic plasma exchange and immune rejuvenation
Dr. Jack Kreindler – Performance and extreme medicine
Dr. Robin Rose – Long COVID, spike protein, and viral impact on aging
Dr. Neil Paulvin – Latest supplements and technology
Dr. Amy Killen – Hormonal health and longevity
Tech, Business & Investment
These leaders are funding and scaling the next $100B wave in longevity.
Naveen Jain – Building a Longevity Tech Unicorn, Founder, Viome
Vania Lacascade, PharmD – Chief Innovation Officer, L’Oréal
Vasanth Jayaraman – Advanced testing technology - COO, Vibrant Wellness
Mark Bernegger – Founding Partner, Maximon Longevity VC
Amol Sarva, PhD – Investing in Longevity - Founder, LifeX Fund
Phil Newman – CEO, Longevity.Technology
Alejandro Bataller – Founder, SHA Wellness
Anant Vinjamoori, MD – Chief Longevity Officer, Superpower
Dr. Darshan Shah – Founder and CEO, Next Health
Dr. Olivier Véran – Former French Minister of Health
Dr. Tsin Uin Foong – Precision Medicine Leader, Asia
Join us in Cannes for the Longevity Docs Summit
📅 June 25–26, 2025 | 📍 Cannes, France
Limited applications now open.
This is your invitation to the most important room in longevity medicine.
Genetic Testing Under Scrutiny: Precision Tool or Clinical Overreach?
This week’s debate revisited the clinical utility of commercial genetic panels like Invitae, Myriad, and New Amsterdam. While many physicians value them for identifying APOE status or hereditary cancer syndromes, concerns remain about how to handle Variants of Uncertain Significance (VUS) and interpret results that lack clear intervention pathways.
“I had a patient with an Invitae VUS that was dismissed — later developed an MI. These aren’t benign.” – Dr. SM
“We’re loading patients with data they’re not ready to carry. It creates anxiety and unclear next steps.” – Dr. TR
“We integrate genomics into hormonal, metabolic, and family history profiles — but it’s not straightforward.” – Dr. FC
Clinical Question: Are broad genomic panels enhancing risk stratification and patient care or adding layers of complexity without clinical clarity?
Bottom Line: Genetic testing has its place - particularly in targeted, high-risk scenarios - but interpretation must be evidence-informed and patient-contextual. Broad panels without solid actionability risk undermining trust and creating diagnostic noise.
What to Watch: As consumer demand grows and panel offerings expand, the burden falls on clinicians to set standards for responsible use. Precision medicine requires precision interpretation.
Cleerly vs. HeartFlow
The chat lit up this week over the two frontrunners in non-invasive coronary imaging. Physicians compared Cleerly, favored for detailed plaque phenotyping, with HeartFlow, known for its virtual FFR capabilities. The conversation highlighted both tools’ strengths, and the gaps in access, especially outside the U.S.
“Cleerly is the gold standard for plaque characterization. Their ischemia analysis is solid, but HeartFlow still wins on FFR.” – Dr. GC
“I’ve had Cleerly analyze data from overseas CCTAs. It works. DM me.” – Dr. MG
“Caristo’s looking good in the UK, but it’s still not available here.” – Dr. VM
Debate: Are we over-relying on plaque morphology without functional validation? Or is FFR alone not enough in the age of inflammation-first cardiology?
Takeaway: Cleerly is leading in plaque inflammation detection, while HeartFlow still holds value for flow-based revascularization decisions. The smartest docs? They’re blending both when they can access them.
Trend Watch: Expect rapid international expansion, partnerships, and maybe even mergers. Everyone wants to own the full cardiac risk picture: structure and function.
Want to be part of the WhatsApp group?
Join 400+ elite longevity physicians exchanging protocols, insights, and clinical breakthroughs in real time.
Welcoming new Members
William Dawson, MD: Leeds, UK
Kevin White, MD: Edmond, OK, USA
Virginia Boccardi, MD: Perugia, Italy
Nishita Ranka, MD: Hyderabad, India
Brooks Leitner, MD: Branford, CT, USA
Allen Gorman, MD: Henderson, NV, USA
Sandeep Palakodeti, MD: Granville, OH, USA
Dannette Kallay, MD: Asheville, NC, USA
Jakub Rzepka, MD: Warsaw, Poland
Private Club Spotlight
Meet the Longevity Doctors Club members: physicians entrepreneurs building the future of longevity medicine one practice (or more) at the time.
Giovanni Campanile, MD, FACC, FAARM
Board-certified Cardiologist | New York City
Dr. Giovanni Campanile is a board-certified cardiologist and functional medicine leader blending evidence-based cardiology, advanced biomarkers, and AI diagnostics to push the frontier of preventive and longevity medicine.
As the former cardiologist to President George H.W. Bush, Dr. Campanile brings decades of high-level clinical experience, grounded in training from Harvard’s Beth Israel Deaconess, Mass General, and the Lahey Clinic. He served on the Framingham Heart Study and has led integrative programs at Rutgers Medical School and Atlantic Health.
Today, through his private practice Functional Heart, he offers longevity-focused patients early cardiovascular risk detection using tools like Cleerly, genomic panels, and personalized biomarker tracking, far beyond traditional cardiac care.
🧠 His mission? To shift cardiology from late-stage intervention to proactive, precision-based prevention.
📍 Caldwell, NJ & Virtual | functionalheart.com
Join the Longevity Docs Club
If you’re a physician starting or scaling your longevity practice highly vetted Longevity Docs Club is for you.
Join a community of like-minded physicians and gain access to resources on marketing, finance, strategy, and technology to support your independent practice
Applications now open for MD, DO, or MBBS - Limited memberships
An Exploratory Multi-reader, Multi-case Study Comparing Transmission Ultrasound to Mammography on Recall Rates and Detection Rates for Breast Cancer Lesions
Three-dimensional Quantitative Transmission (QT) ultrasound imaging is an emerging modality for improving the detection and diagnosis of breast cancer. QT ultrasound has high resolution and high contrast to noise ratio, making it effective in evaluating breast tissue. This study compares radiologists’ performance of noncancer recall rates and lesion detection rates using QT Ultrasound versus full-field digital mammography (FFDM) in a cross section of female subjects. American Radiology (2022)
The impact of 3,3’-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patch
A new study suggests that the supplement 3,3’-diindolylmethane (DIM), often used in functional medicine, may significantly alter estrogen metabolism in postmenopausal women using transdermal estradiol (E2) patches. Analysis of over 1,400 cases revealed that those concurrently taking DIM showed changes in six key urinary estrogen metabolites. These shifts could potentially reduce the clinical impact of menopausal hormone therapy (MHT), raising important considerations for practitioners managing MHT dosing and outcomes. Menopause (2025)
Adherence to lifestyle intervention activities in the SINgapore GERiatric to reduce cognitive decline and physical frailty (SINGER) study: A one-year preliminary analysis of process evaluation
In the SINGER study, over 70% of older adult participants demonstrated moderate to high adherence to a 1-year lifestyle intervention aimed at preventing cognitive decline and frailty. Using Latent Class Analysis, three adherence profiles were identified: high (62.1%), moderate (23.9%), and low (14%). Women, individuals with higher education, and those not living alone showed better adherence. Participants engaged most with diet and vascular activities, less with cognitive tasks. Simpler, in-person activities had better adherence. Hypertension was linked to higher overall participation but lower attendance at vascular sessions. The study suggests simplifying complex activities and tailoring support for vulnerable groups to boost engagement. Geroscience (2023)
NAD depletion in skeletal muscle does not compromise muscle function or accelerate aging in mice.
A new study challenges long-held assumptions about NAD+ and aging. Researchers induced an 85% drop in NAD+ levels in mouse skeletal muscle by disrupting NAMPT-mediated biosynthesis. Despite this significant depletion, muscle strength, mitochondrial function, exercise tolerance, and aging markers remained unaffected. These results suggest that NAD+ depletion alone may not drive age-related muscle decline, reshaping how we think about NAD+ in longevity science. Cell Metabolism (2025)
We track the week’s most strategic moves in innovation, funding, product launches, and talent shifts. This is not just to report them, but to help doctors stay informed, ahead, and equipped to adapt as the field evolves.
Because the future of longevity medicine is being built in real time and you deserve a front-row seat.
Cancer Screening Startup Craif Raises $22M to Expand AI Urine Diagnostics
Japanese biotech Craif secured $22M Series C funding to expand into the U.S., bringing total funding to $57M and valuation near $100M.
Why it matters:
Craif uses AI and urinary microRNAs to detect cancers at Stage 1 via a non-invasive test - already adopted by 20,000+ users across 1,000 clinics in Japan. It’s now targeting U.S. FDA trials and commercial rollout.
Takeaway:
Craif’s platform, miSignal, could reshape early detection with simpler, cheaper, and more accurate testing, starting with 7 cancers, expanding to 10 and even neurodegenerative diseases.
Trend watch:
Liquid biopsies via urine + AI are emerging as the next wave in preventive diagnostics with lower cost and higher precision than traditional cfDNA blood tests.
AI Agent Hospital Launches in China
AI Agent Hospital, launched by Tsinghua University on April 26, is China’s bold step toward embedding intelligent agents into hospital operations, with AI assisting doctors in diagnosis, treatment, and decision-making.
Why it matters:
In partnership with Beijing Tsinghua Changgung Hospital, the AI hospital is piloting services in general practice, radiology, ophthalmology, and respiratory care, aiming to scale efficient care delivery where physician shortages persist.
Takeaway:
Tsinghua is also training a new generation of AI-collaborative physicians -doctors educated to work alongside AI, not be replaced by it- laying the groundwork for a hybrid care model across China.
Trend Watch:
This marks a shift toward “AI + Healthcare + Education + Research” ecosystems, signaling that future hospitals may function more like operating systems than buildings with longevity care at the core.
AI Health Coach Terra Launches from InsideTracker, Bringing Concierge Guidance to Your Biomarkers
InsideTracker has unveiled Terra, an AI-powered virtual health coach that merges GPT-4 with expert-level reasoning (KRR) to deliver personalized, biomarker-driven guidance based on bloodwork, sleep, supplements, genetics, and lifestyle data.
Why it matters:
Terra is the first AI system to combine clinical-grade health insights with real-time conversational coaching without hallucinations. It filters every recommendation through personal data and InsideTracker’s science-backed knowledge base, making it a credible step beyond generic health chatbots.
Takeaway:
Terra turns your bloodwork into a dialogue, helping you troubleshoot symptoms, interpret results, and optimize health habits with precision. It’s like having a concierge doctor trained on your data—available instantly, securely, and at scale.
Trend Watch:
This marks the arrival of Dual AI Systems (LLM + KRR) for health, merging scientific rigor with conversational UX. Expect more platforms to follow, but few will have the depth of InsideTracker’s clinical integration.
Hims & Hers Partners with Novo Nordisk to Offer Wegovy at $599/Month
Hims & Hers has teamed up with Novo Nordisk to offer direct access to the weight-loss drug Wegovy via its virtual care platform, bundled with 24/7 clinical support, nutrition guidance, and digital coaching for $599/month.
Why it matters:
This marks a major move in consumerized chronic disease management, with GLP-1 medications like Wegovy now reaching patients outside traditional healthcare channels. With U.S. obesity rates at record highs, digital-first access could dramatically increase demand and engagement.
Takeaway:
Hims & Hers now connects cash-paying users directly to NovoCare Pharmacy, bypassing insurers while providing concierge-style services. This follows similar partnerships between Novo and Ro and LifeMD, who are also offering Wegovy at $499/month.
Trend Watch:
As telehealth meets pharma, expect more vertically integrated DTC models combining prescription drugs, continuous care, and AI coaching: especially in the weight-loss, metabolic, and longevity space.
Longevity Docs Summit Cannes
This is not just another medical conference, this is the future of cutting-edge longevity medicine.
Join the world’s most visionary longevity physicians, scientists, and innovators for two days of breakthroughs, discoveries, and high-level networking under the French Riviera sun.
Summit. Awards & Black tie Gala. Expo.
📅 Date: June 25-26, 2025
📍 Location: Palace of Festival, Cannes - France
🎟️ Registrations are now open: and spots are limited.
👉 Apply now before it sells out. The New Gods of Medicine will be in Cannes. Will you?
Hormones Mastermind Replay
For the first time, get full online access to the entire event:
✔ 10 expert-led modules
✔ Real-world protocols and case studies
✔ On-demand viewing, anytime, anywhere
No fluff, no travel: just pure, actionable hormone and longevity education.
Replay Pass: $295
Longevity Conferences Calendar
A4LI DC Summit: Washington DC - April 28-30
The Longevity Med Summit - Lisbon, May 6-8
Life Summit - Berlin, May 27-28
Dublin Longevity Summit: Dublin, July 2–4
ARDD: Coppenhagen, August 25-29
Why every doctor should be a longevity doctor.
The Movement
Longevity Docs is the world’s leading collective of physicians advancing longevity medicine through education, clinical research, advisory, and exclusive experiences. With over 400 members in 50+ countries, we’re building the global infrastructure for evidence-based, personalized longevity care.
Why “Longevity Docs”?
Because we believe longevity is not a specialty — it’s a human right.
The future of medicine is proactive, not reactive. It's interdisciplinary, not isolated. It’s collaborative, data-driven, and deeply human. And it starts with us — the physicians who dare to redefine what care looks like across the decades of a patient’s life.
“Longevity Docs” isn’t just a name. It’s a statement of purpose.
Our Ecosystem
Physician Network
A trusted global collective of longevity-focused doctors exchanging protocols, referrals, and real-world clinical outcomes.Education & Certification
Earn your Certified Longevity Physician™ designation through our advanced curriculum, live masterclasses, and continuous learning tracks.Decentralized Research
Lead or participate in multicenter clinical trials and patient registries, accelerating evidence generation for healthspan optimization.Strategic Advisory
We partner with vetted longevity companies, life-science, tech, and clinics to help them grow.Global Events & Experiences
Access exclusive gatherings like the NYC Mastermind and the Cannes Longevity Summit & Awards
Who It’s For
Doctors → Join the club, get certified, grow your practice
Health Systems → Implement clinical longevity programs
Brands & Startups → Validate products, find advisors, run trials
Investors → Gain early access to insights, doctors, and deal flow
Subscribe to the Longevity Docs Newsletter
Stay connected with the backstage of the Longevity Docs community, a network of over 400 physicians spanning 50 countries, united in our mission to democratize longevity medicine. Explore the latest in evidence-based longevity care, gain exclusive access to physician insights, and join us in shaping the future of this transformative field.
Newsletter Disclaimer:
The content shared in this newsletter, including the "Buzz in the Chat" section, is for educational purposes only. It is derived from peer-to-peer conversations among physicians within the Longevity Docs community and is intended to inform and engage our network of doctors.
Please note that these discussions do not reflect the official position of Longevity Docs and are not to be interpreted as medical advice or recommendations. The insights and opinions shared are those of individual physicians and are provided as part of our mission to foster collaborative learning and dialogue among healthcare professionals.
We encourage all readers to consult qualified healthcare professionals for personalized medical advice and to evaluate any medical information in the context of their clinical expertise and patient needs.
Great write up as usual, David. Merci, Salomé